A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm

Clin Pharmacol Ther. 2013 Aug;94(2):224-9. doi: 10.1038/clpt.2013.9. Epub 2013 Jan 17.


The promise of genomic medicine has received great attention over the past decade, projecting how genomics will soon guide the prevention, diagnosis, and treatment of human diseases. However, this evolution has been slower than forecast, even where evidence is often strong (e.g., pharmacogenomics). Reasons include the requirement for institutional resources and the need for the will to push beyond barriers impeding health-care changes. Here, we illustrate how genomics has been deployed to advance the treatment of childhood leukemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomedical Research
  • Chromosome Aberrations
  • Core Binding Factor Alpha 2 Subunit / genetics
  • Decision Support Systems, Clinical / organization & administration
  • Genetic Testing
  • Genetic Variation
  • Genomics
  • Genotype
  • Humans
  • Oncogene Proteins, Fusion / genetics
  • Pediatrics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Risk Assessment


  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • TEL-AML1 fusion protein